Gilead Sciences Reports Strong Cure Rate for Hepatitis C Drug
MINYANVILLE ORIGINAL Gilead Sciences (NASDAQ:GILD) took another step forward with its hepatitis C drug program Tuesday showing a strong cure rate for hard-to-treat patients in a late-stage study. The data met Wall Street expectations and is significant because it is the first of several trials in the final round -- or so-called Phase III stage -- of study necessary to win US approval. The company is expected to announce three more Phase III trial results in the first quarter of 2013 and will likely file for US Food and Drug Administration approval for its drug sofosbuvir by the middle ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here